Herpes zoster vaccine (HZV): utilization and coverage 2009 – 2013, Alberta, Canada by Xianfang C Liu et al.
Liu et al. BMC Public Health 2014, 14:1098
http://www.biomedcentral.com/1471-2458/14/1098RESEARCH ARTICLE Open AccessHerpes zoster vaccine (HZV): utilization and
coverage 2009 – 2013, Alberta, Canada
Xianfang C Liu1†, Kimberley A Simmonds2†, Margaret L Russell1*† and Lawrence W Svenson1,2,3†Abstract
Background: Herpes zoster vaccine (HZV) is not publicly funded in the province of Alberta, Canada. We estimated
vaccine coverage among those aged 60 years or older for 2013, as well as vaccine utilization rates per hundred
thousand population over the period 2009 – 2013. We explored for factors associated with HZV dispensing rates.
Methods: We used administrative data from the Alberta Pharmaceutical Information Network (PIN) database to
identify unique persons for whom HZV had been dispensed from community pharmacies over 2009 – 2013. PIN data
were also used to estimate the pharmacy/population ratios for rural and urban Alberta over the period. Denominators
for rates were estimated using mid-year population estimates from the Alberta Health Care Insurance Plan Registry.
Income quintile data were estimated from the 2006 Census of Canada. Crude, age, sex, geographic (rural vs. urban),
income-quintile and year specific rates of HZV vaccine dispensing were estimated per 100,000 population. Rates were
adjusted for pharmacy/population ratio. Vaccine coverage for persons aged 60 years or older was estimated using counts
of all unique persons for whom the vaccine was dispensed over the period in the numerator and a 2013 mid- year
population denominator.
Results: HZV dispensing rates rose annually from 2009 – 2013. Vaccine coverage was estimated to be 8.4% among
persons aged 60 years or older. Rates of dispensing were highest for persons aged 60–69 years and were higher for
females than males and for persons from higher compared to lower income quintiles. Dispensing rates were lower
for rural than for urban residents. About 2% of vaccine was dispensed for persons aged less than 50 years.
Conclusions: Rates of HZV dispensing are increasing rapidly in Alberta despite a lack of public funding. A small
proportion of the vaccine may be dispensed off-label.Background
Monitoring trends in both disease and vaccination are
important components of disease control programs [1] for
vaccine preventable diseases. Varicella-zoster virus causes
two distinct diseases: varicella (chickenpox) and herpes
zoster (shingles). Different vaccines have been developed
for the prevention of these diseases: varicella vaccines for
the prevention of chickenpox, and herpes zoster vaccine
(HZV) for the prevention of shingles [2]. Shingles can occur
both after a primary infection with wild varicella virus and
after vaccination with live attenuated varicella vaccine; al-
though the risk of shingles, at least in healthy vaccinated
children, is less than after having chickenpox disease, and* Correspondence: mlrussel@ucalgary.ca
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unless otherwise stated.the disease milder [3,4]. To monitor varicella zoster virus,
surveillance programs should include surveillance for both
diseases and population coverage for both vaccines.
In Alberta, Canada, a publicly funded varicella vaccin-
ation program for chickenpox has existed since 2001; a
single dose is recommended for children age 12 months
or older and coverage has exceeded 80% since 2005 [5].
Current immunization rates in Alberta are estimated to
be just under 85% [6]. Other studies have addressed the
epidemiology of chickenpox [7,8] and shingles [5,8,9] in
the periods prior to and after public funding of chicken-
pox vaccine. In 2008, a live attenuated HZV was autho-
rized for use in Canada for the prevention of herpes
zoster infection in adults aged 60 years and older [10];
and the authorization subsequently expanded to include
persons aged 50 years or older in 2011 [11]. The vac-
cine was licensed in the U.S.A. in 2006 and the United
States Advisory Committee on Immunization PracticesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Number and proportion of doses of herpes
zoster vaccine dispensed by age-group and geography
(rural/urban) 2009 - 2013
Age group N doses dispensed Total N doses
dispensed (%)
Rural Urban
< 5 years – 49 years 191 1,216 1,407 (2.0)
50-59 years 1,877 14,577 16,454 (23.9)
60-69 years 3,940 25,381 29,321 (42.5)
70-79 years 2,293 13,936 16,229 (23.6)
80 years or older 672 4,842 5,514 (8.0)
TOTAL 8,973 59,952 68,925 (100)
(Geographic data were missing for 95 persons).
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[12,13]. In 2010, the Canadian National Advisory Com-
mittee on Immunization (NACI) recommended that the
vaccine be used for all persons aged 60 years or older
who did not have a contra-indication, and indicated
that it may be used in persons aged 50 years and older
[10]. The vaccine is administered as a single dose. Al-
though the vaccine is not publicly funded in any Canadian
province or territory [14], it is available for private
purchase in Alberta through community pharmacies. We
examine the epidemiology of population utilization of
HZV vaccine (Zostavax™) in Alberta over the period of
2009 – 2013 using population-based dispensing data
for community pharmacies. We estimate HZV coverage
among persons aged 60 years or older, as well as for
persons aged 50 years or older for 2013.
Methods
We used administrative health data from the Alberta
Pharmaceutical Information Network (PIN) database to
capture the number of unique persons for whom HZV
vaccine was dispensed in Alberta as well as a count of
the number of pharmacies with a dispense event for any
prescription pharmaceutical in each year for the period
2009 – 2013. The study was approved by the University
of Calgary Conjoint Health Research Ethics Board
(Protocol 23776). Written informed consent from partic-
ipants was not required as the data custodians released
only anonymous aggregated data to the investigators. In
Alberta, hospital pharmacies dispense only to patients
while they are hospitalized; prescription pharmaceuticals
(including prescriptions that are written at the time of
hospital discharge) are otherwise dispensed from com-
munity pharmacies. All pharmacists working in commu-
nity pharmacies are mandated to submit drug dispensing
information to the Alberta Ministry of Health for entry
into PIN since September 1, 2007 [15]. PIN is estimated
to capture information on more than 95% of the drugs
and biologicals dispensed by community pharmacies
[16]. This system, updated on a daily basis, captures
information on dispensing of vaccines and drugs, as well
as a unique personal identifier (PHN) for the person for
whom the vaccine/drug is dispensed and a unique iden-
tifier for the pharmacy from which the drug or vaccine
was dispensed. The system captures all medications dis-
pensed by the pharmacy regardless of patient insurance
status [17]. The PHN can be linked to the Alberta Health
Care Insurance Plan Registry from which the date of birth
and address of the individual were obtained. Postal codes
of residence that included a zero in the second place of the
six-digit postal code were classified as rural [18,19]. Rural
and urban income quintiles for Alberta (aggregated at the
level of postal code) were calculated from 2006 Canada
census data using methods similar to those of Martens andcolleagues [20]. File linkage and data extraction were con-
ducted by employees of Alberta Health (data custodians)
for the period 2009–2013, and the data aggregated for priv-
acy protection prior to release to the researchers.
Denominators for rates were estimated using mid-year
population estimates from the Alberta Health Care
Insurance Plan Registry [21] which has been shown
to be a reliable population data source [22]. Data were
analyzed using SAS 9.3 (SAS Institute Inc., Cary, NC
2011) and graphs created using SigmaPlot Version 12.5
(Systat Software, San Jose, CA 2013). Annual age-, sex-,
geography-, and income quintile-specific rates were
estimated. A population level HZV coverage rate was
estimated by taking all individuals filling a prescription
for vaccine during the study period and linking them
with the 2013 mid-year population file from the Alberta
Health Care Insurance Plan Registry. This approach
allowed for the removal of individuals who died or moved
out of province.
The crude relative risk of HZV vaccine dispensing
rates was calculated using modified Poisson regression
with robust error variances [23]. The reference group
used in the analysis was the 50–54 year old age group.
Negative binomial regression was used to explore for
age group (5-year age-group), sex, geography (rural vs.
urban), income quintile, pharmacy/population ratio and
year effects and their interactions for persons aged
50 years or older. A forward stepwise approach was used
to construct a model with the best fit where all terms
were significant predictors of the outcome at alpha = 0.05.
To a model that contained main effects for each of
age-group, sex, geography, year, income quintile and
pharmacy/population ratio we added the two-way inter-
action terms sequentially, at each step examining the
likelihood ratio statistic at alpha = 0.05.
Results
Table 1 shows dispensing data by age group and geog-
raphy. Over the period 2009 – 2013, 69,020 unique
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from 279 individuals in 2009 to 34,427 in 2013. Most of
the vaccine (87%) was dispensed to urban residents. The
largest proportion of vaccine was dispensed to persons
aged 50 years or older. Vaccine was most frequently
dispensed to persons aged 60–69 years; 42.5% of all
HZV that was dispensed. About 2% of vaccine was
dispensed to persons aged 5–49 years.
HZV dispensing rates among persons aged 50 years or
older increased every year in all age-groups (Figure 1).
Within each year, the dispensing rate increased steeply
among younger persons, peaked for age-group 65–69
years and then declined. Dispensing rates for both males
and females began to sharply increase in 2011 but were
higher in every year for females compared to males
(Figure 2). However for both sexes, the pattern of in-
creasing rates for both males and females by age group
over the period was consistent: increasing to a peak for
age-group 65–69 years, and then declining (Figure 3).
There was a sharp increase in dispensing rates among
both rural and urban residents in 2011 although rates
were consistently higher for urban compared to rural
residents in every year (Figure 4). As can be seen in
Figure 5, dispensing rates increase for both males and
females by income quintile.
Taking all people that filled a prescription between
2009 and 2013 and who were still residents of Alberta in
2013, a population coverage estimate was calculated to
be 8.4% for individuals aged 60 years and older. Among
those aged 60 years or older, coverage was 7.2% and
9.5% for males and females, respectively. Individuals
living in urban centers had higher coverage than those
in rural areas (8.8% vs. 6.6%). Among those aged 50 years
or older, coverage was 6.1% for the population as a
whole (4.8% for males, 7.3% for females). Individuals
living in urban centers had higher coverage than those
in rural areas (6.2% vs. 5.3%).Figure 1 HZV dispensing rates by age-group and year, persons agedThe variables included in the final multivariable model
were geography, age-group, sex, year, income quintile,
pharmacy/population ratio, and the two-way interactions
between geography*year, geography*income quintile, and
age-group*sex (Table 2).
Discussion
The dispensing of HZV has substantially increased in
Alberta over the period 2009 – 2013. In Canada, al-
though the vaccine was licensed in 2008 and NACI indi-
cated that the vaccine could be used in persons aged
50 years or older in 2010 [10], the vaccine was not au-
thorized for use among people aged 50 years or older
until 2011 [11]. In Canada physicians are advised, from a
medico-legal perspective, that they should make patients
aware of information including “official recommenda-
tions from authoritative groups, such as governments
and medical specialty associations” [24]. This may ex-
plain in part why dispensing rates increased sharply
starting in 2011. The increasing rates since that time
may be reflective of increased patient awareness or re-
quests for vaccine due to the influence of one or more
of physicians providing information or recommenda-
tions, pharmacists providing information or vaccination
services and/or direct to consumer marketing by manu-
facturers [14].
Rates of vaccine dispensing were lower for rural com-
pared to urban residents, even after adjusting for sex,
age-group, income quintile and ‘access to pharmacies’
(pharmacy/population ratio) in our model. However,
pharmacy/population ratio is a blunt measure of access,
and does not take into account that there might be a re-
quirement to travel a greater distance to access a service
in a rural compared to an urban area [25]. Rural Alberta
residents have access to fewer healthcare providers per
thousand population than do urban residents [25] thus it
is also possible that the observed rural/urban difference in50 years or older, Alberta 2009–2013.
Figure 2 HZV dispensing rates among persons aged 50 years or older by year by sex, Alberta 2009–2013.
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physicians as vaccine must be prescribed before it can be
dispensed.
In Alberta, HZV is not publicly funded and not cov-
ered by the publicly funded provincial drug insurance
plan for seniors [26]. Despite the lack of public funding,
we estimate population coverage among persons aged
60 years or older to be 8.4%. In 2011, among members
of Kaiser Permanente Southern California (a population
insured for HZV), HZV coverage among those aged
60 years or older who did not have a contraindication to
vaccination was an estimated 20.7% , compared to anFigure 3 HZV dispensing rates for females and males by age groupsestimated 15.8% in the U.S. general population, a mix-
ture of persons with and without insurance [27]. It is
not surprising given the lack of public funding that
Alberta coverage rates were lower than those observed
in the United States; however, funding may be only one
factor that contributes to the differences. Aside from the
effect of other determinants of health, the promotion of
vaccination can be facilitated by having population goals.
In the United States, there is a Healthy People 2020
target of 30% population coverage among persons aged
60 years or older [27]. In Canada there are no national
goals or targets for HZV [28].in Alberta, 2009–2013.
Figure 4 HZV dispensing rate by geography (rural and urban communities) in Alberta, 2009–2013.
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drug was reported by 4.8% of people aged 65 years or
older [29]. The results of our model showed that persons
of higher, compared to lower income were more likely
to be dispensed HZV. Public funding of the vaccine
might reduce the impact of income quintile on being
vaccinated. In Alberta there has not been evidence of
health disparity in terms of shingles by income [8];
however this was prior to the licensure of HZV. The ob-
served association between income quintile and vaccine
dispensing suggests that ongoing monitoring of shingles
and vaccine dispensing by some measure of income isFigure 5 HZV vaccine dispensing rate for females and males by incomimportant as this picture may change over time in the
absence of public funding for HZV.
Females were still more likely than males to be dis-
pensed the vaccine even after adjustment for income
quintile. Others have found that females were more
likely than males to accept HZV [27,30]. These studies
were conducted among populations for which HZV was
either covered by insurance for most participants, or
provided for free. In a managed care organization in the
United States where most of the study participants had
insurance coverage for HZV, vaccine uptake was found
to be highest in the age group 65–74 years, and highere quintile in Alberta, 2009–2013.
Table 2 Predictors of HZV dispensing rates for those
aged 50 years or older*
Variables Reference group OR1 95% CI2
Rural geography Urban 0.68 0.53-0.87
Female sex Male 1.44 1.35-1.53
Age group 50-54




































*Adjusted estimates: adjusted for rural/urban geography, sex, 5-year age
group, year, income quintile and 2-way interaction terms, ratio of
pharmacies/total population.
1OR = odds ratio.
295% CI = 95% confidence interval.
3Q1 = income quintile 1 (lowest income quintile).
Liu et al. BMC Public Health 2014, 14:1098 Page 6 of 8
http://www.biomedcentral.com/1471-2458/14/1098among females than males [27], a similar pattern to what
we observed. As part of an annual influenza vaccination
campaign, Opstelten and colleagues in the Netherlands
[30] offered free HZV in addition to influenza vaccine to
patients aged 65+ in primary care practices. Females
were more likely than males to accept HZV by itself or
with influenza vaccine. Gender associations may reflect
multiple factors including differences in perception of
risk or health service utilization. In the Netherlands, rea-
sons for refusing HZV included perceptions that the risk
of shingles and/or the severity of shingles was low, that
the general practitioner (GP) had not recommended the
vaccine and that it was difficult to attend the GPs office
for vaccination [30]. Lee and colleagues [31] studied pa-
tients attending academic primary care practices in the
USA. The cost of HZV was covered by health insurance
for the majority of participants. Patients who had seen a
person with shingles were more likely to be vaccinated,
or if not vaccinated, more likely to be interested in being
vaccinated than those who had not. In the same study,
participants listed reasons for being vaccinated as in-
cluding both recommendations from doctor (42%) and
recommendations from media/advertising (32%). Thus it
is possible that Alberta females compared to males may
differ in their perceptions of disease risk or severity,
and/or be more likely to have received a positive recom-
mendation to be immunized from a trusted health care
provider. The incidence of shingles has been observed to
be higher in females than males in studies from several
countries [5,32-35]; although it is possible that this pat-
tern might be due to differences in health care seeking
behavior. Even if the difference in disease epidemiology
is an artifact of differences in health care seeking behav-
ior, it is possible that females compared to males may
differ in one or more of perceptions of risk of disease,
disease severity, or having seen a person with shingles,
factors found by others to be associated with accepting
HZV [30,31].
It is interesting that rates of HZV dispensing declined
for both males and females aged over 70 years compared
to rates for younger persons. A similar pattern has been
observed by others: rates increase with age up to a point
and then decline [27]. We do not think this can be
explained by a decrease in physician utilization by
age (a possible marker for age-related decreasing op-
portunities to be prescribed HZV), as physician utilization
does not decrease with age among older persons in Alberta
(Alberta Health, unpublished data). We hypothesize that
older persons might be cumulatively more likely to have
had shingles than younger persons, thus be less likely
to receive a recommendation or prescription for HZV.
In Canada, NACI made an explicit statement in 2010
that there was no recommendation for immunizing per-
sons with a history of shingles [10]. It is possible that
Liu et al. BMC Public Health 2014, 14:1098 Page 7 of 8
http://www.biomedcentral.com/1471-2458/14/1098physicians interpreted this to mean that they should
not recommend the vaccine to these persons. NACI
changed position on this in 2014 and now states that
“Herpes zoster vaccine may be administered to individ-
uals ≥50 years old with a prior history of herpes zoster”
[36]; thus the age-related pattern of HZV dispensing
may change in the future.
Persons who received HZV outside of the province of
Alberta would not be captured in the PIN database.
However, only 1.2% of seniors moved from one province
to another between 1996 and 2001 [37], thus although
our coverage estimates might be underestimates, we
perceive that this bias is likely to be small, particularly
for those aged over 60 years.
We have assumed that doses of vaccine that are dis-
pensed are actually administered, if this is not the case
then we have overestimated HZV utilization and vaccine
coverage. The PIN database captures data from commu-
nity pharmacies, and thus would not capture any doses
of vaccine that were dispensed from either by a hospital
pharmacy or via a physician office. We think the former
unlikely, but have no data to assess this. Physician of-
fices, however, could directly order vaccine for patients
and administer it at a charge to the patient. We think
this unlikely to have occurred due to the complexity
of storage and handling requirements for the vaccine.
Zostavax™ is the sole HZV that is authorized for use in
Canada, and it must be kept frozen, then used within
30 minutes of reconstitution [10]. Further, in Alberta
physicians have a limited role in immunization as rou-
tine immunizations except for influenza immunization
are provided exclusively through public health clinics.
Thus, Alberta physicians may be less likely than those in
other provinces to invest in appropriate storage facilities
and staff training for a vaccine that requires more than
refrigeration.
We note that HZV was dispensed to persons
aged < 50 years in our data, although this accounted
for only about 2% of the vaccine dispensed. This might
represent off label prescribing/dispensing: use beyond the
criteria covered in the approval granted by Health
Canada [38]. Future research should determine if such
is the case and if such practices are beneficial to the
patient.
It is possible that the PIN data misclassified persons,
especially those under the age of 50 years as having
received HZV when a different vaccine was actually
dispensed, although we think this unlikely. We perceive
that the most probable error that might occur would be
the entry of an incorrect Drug Identification Number
(DIN), particularly that of entering a DIN for HZV when
a DIN for varicella vaccine should have been entered.
Varicella vaccine is publicly funded in Alberta, including
for adults. Publicly funded vaccines are not dispensedthrough community pharmacies, thus are not recorded
in PIN. Between 2009 and 2013, there were less than
100 prescriptions filled for varicella vaccine according to
PIN (Alberta Health, unpublished data). Assuming this
was the most common mis-coding of vaccine, the im-
pact on overall coverage by year would be minimal.
There is also a small possibility that pharmacists entered
an incorrect personal health number into PIN, although
this would increase the likelihood that an incorrect
name (corresponding to the incorrect personal health
number) would also be listed on the prescription as
filled, so that such errors would be promptly identified
at the time of the dispense event. This would, if not
corrected at the time of the dispense by the pharmacist
(pharmacists are trained to double check the names of
the persons to whom dispenses are made against the
prescription scrips), still result in the correct number of
dispenses for the vaccine, but might introduce errors for
age-specific rates. We think the impact of this, did it
occur, would be small.
PIN is unique in capturing drug and biological dis-
pensing regardless of insurance status as these data are
not currently captured in the Alberta immunization
registry. PIN data have proven useful in validating dis-
pensing data for pharmaceutical dispensing from other
sources [39]. PIN data, because they are not subject to
recall, could also be used to validate self-reports of HZV
immunization from a population survey and can con-
tribute to estimations of population coverage with HZV.Conclusions
The rate of dispensing of HZV in Alberta has been rap-
idly increasing without public funding for this vaccine.
Monitoring HZV uptake should continue regardless of
public funding as it is an important component of sur-
veillance of the impact of varicella (and of HZV) vaccin-
ation on the incidence of shingles.
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